Empathizing with the drug industry may be tough these days, especially if you just emptied your wallet to pay for your prescription or rode a Greyhound to Canada to buy the same medicine for less. But just for a moment, put yourself in the shoes of pharmaceutical executives who last week attended a conference in Boston on the latest practice to tarnish their trade: the sale and illegal marketing of drugs for "off label" uses not approved by the FDA. "Rarely has a conference been more timely," warned James Dillon, a partner at Foley Hoag, the Boston-based law firm that sponsored...
To continue reading:
or
Log-In